You are here

Study: 3D Mammography Reduces Recall Rates

Cancer detection also increased (May 23)

The first large-scale observational study in a U.S. clinical practice comparing breast cancer screening with 3D mammography technology (breast tomosynthesis; Hologic, Inc.) versus conventional 2D mammography has shown a significant reduction in recall rates and an increase in cancer detection, particularly invasive cancer, across all breast-tissue densities.

Published in the June issue of the American Journal of Roentgenology, the study evaluated recall, biopsy, cancer detection, and invasive cancer detection rates in a community-based breast-imaging practice. The study was issued online in advance of print on May 23.

The analysis compared the outcomes of 2D mammography screening exams that were interpreted prior to the introduction of 3D mammography, with screening exams after the introduction of 3D mammography into the practice.

In the study, the use of 3D mammography resulted in:

  • A significant 38% decrease in recall rates — from 8.7% to 5.5% (P
  • An 11% decrease in biopsy rates — from 15.2 to 13.5 per 1,000 screenings (P = 0.59)
  • A 35% increase in cancer detection rates — from 4.0 to 5.4 per 1,000 screenings (P = 0.18)
  • A 53% increase in invasive cancer detection rates — from 2.8 to 4.3 per 1,000 screening examinations (P = 0.07)

The study population included 13,856 women who had received conventional 2D mammography screening exams and 9,499 women who elected to receive a 3D mammography screening exam. The images were interpreted by one of six radiologists with an average 12 years of reading experience.

3D mammography technology was approved for use in the U.S. for breast cancer screening and diagnosis in February 2011.

Source: Hologic, Inc.; May 23, 2013.

Recent Headlines

U.S., Australia, and Canada Approve Endometrial Cancer Regimen
Single daily pill combines hypertension, cholesterol drugs
Drug With Androgen Deprivation Therapy Cut Risk of Death by 33% Compared With Placebo + ADT
A Diabetes Drug For People Without Diabetes
Roche Drug Outperformed Standard of Care in Phase 2 Study
One in Five Kids’ Office Visits Results in an Off-Label Rx
Related Settlement Would End Many but Not All Lawsuits
Chronic Kidney Patients With Hyperphosphatemia May Be Another Market for the Drug
Nitrosamine Impurity Also Affects Other Ranitidine Drugs